Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,710 total articles
US Foods is trading like a dependable distributor benefitting from consumer trade-downs and consolidation in foodservice. With $959M in free cash flow, a $20.16B equity value and an EV/EBITDA of 15.0, the business is cash-generative and relatively insulated versus restaurants and consumer discretionary names. We present a mid-term (45 trading days)…
Mastercard (MA) pulled back on recent risk-off flows and dividend timing, creating a clean entry for patient traders. The company still posts high-margin, high-cashflow economics - market cap $444.8B, free cash flow ~$17.2B and ROE north of 190% - while valuation sits at a reasonable multiple for growth at ~29.7x earnings. We upgrade to Buy and rec…
CoreWeave rallied on multi-year deals with Meta and Anthropic and fresh financing; technical momentum and volume suggest a sustainable uptrend. Valuation is rich, execution risk is real, but current price action offers an asymmetric trade when sized and managed properly.
Redwire sells specialized space infrastructure and has accumulated a string of government contracts and analyst optimism that could re-rate the stock. At a $1.78B market cap, improving program mix and a potential margin inflection make RDW a high-risk, high-reward swing trade. Entry $9.00, target $15.00, stop $6.50.
Capital One's transformative moves - notably the Discover deal and Brex tuck-ins - have materially changed the firm's revenue profile but introduced integration execution risk and greater exposure to subprime credit cycles. At $193, the shares look reasonably valued on tangible book and cash flow, but outsized P/E and rising credit noise argue for …
UnitedHealth (UNH) is a battered franchise trading at $304.80 with a $276.3B market cap, 2026 EPS of $13.28 and free cash flow of $16.08B. Recent CMS Medicare Advantage rate tailwinds and Optum-driven efficiency improvements underpin a constructive mid-term trade. I'm advocating a tactical long: entry $305.00, target $360.00, stop $285.00, mid-term…
Credo (CRDO) reported blowout top-line growth and industry-leading margins, but a post-earnings optics-driven pullback and repeated headlines about customer concentration scared momentum traders. That dynamic has left a tradeable entry: buy now with a tight stop under the recent moving-average cluster and a mid-term target that assumes multiple exp…
Ultragenyx plunged after Phase III setbacks for setrusumab and has since priced in meaningful legal and clinical risk. With a market cap around $2.25B, roughly $1.1B in cash on the balance sheet and an enterprise value of $1.87B, the company can fund operations and pivot while the market digests potential settlement outcomes, upcoming corporate upd…
Gambling.com appears to be stabilizing after a protracted SEO-driven decline. A combination of the OddsJam acquisition, recent beats, and improving technicals argue for a tactical long. This trade idea sets an entry near current levels, a tight stop below the recent low, and a clear upside target that respects the company's small-cap risk profile.
Delta Air Lines looks like a trade you can tilt in your favor: operational resilience shown in recent results offsets an acute sensitivity to jet-fuel shocks. With jet fuel cited as up 88% in recent headlines, this idea pairs a disciplined entry, a sensible stop, and two layered targets to capture a recovery if capacity discipline and travel demand…
Jackson Financial (JXN) trades at roughly $101.62 with a market cap near $7.15B, price-to-book around 0.7 and a dividend yield in the low-3% range. The company’s conservative balance sheet - debt-to-equity about 0.2 and EV/EBITDA near 7.6 - gives it resilience if private credit stress continues to spook insurers. This trade targets a mid-term re-ra…
GE Vernova has moved from an early post-spinoff growth story into a business with sizable backlog, recurring services revenue and order momentum. The market is pricing the company like a pure growth hardware play; I think that underestimates the stability and cash-generating profile Vernova already displays. This is a defined mid-term trade to capt…
Ingles Markets has climbed to multi-month highs, but valuation metrics and cash generation still leave room for upside. This trade buys a measured dip to take advantage of low P/S and EV/EBITDA multiples, strong free cash flow and modest leverage. Manage risk with a firm stop and a mid-term horizon of 45 trading days.
Maple Leaf Foods has seen a valuation reset as investors reward improving margins and a clearer strategic focus on branded protein. Although recent line-item financials were not available in the materials I reviewed, the company's operational momentum and several near-term catalysts support a mid-term long trade. Entry at $17.50, target $21.00, sto…
Micron is benefitting from a multi-year AI-driven surge in high-bandwidth memory and SSD demand. The company posts strong profitability metrics, $10.3B in free cash flow and a conservative balance sheet, yet trades at a reasonable multiple versus its growth run-rate. This trade plan buys MU at $420.70 with a $360 stop and a $520 target over a 180-t…
Eastman Chemical (EMN) traded higher earlier this year, but a pullback has rehypothecated the risk/reward in favor of buyers. With a market cap near $8.5B, P/E around 18x, EV/EBITDA ~8.7x, and a 4.5% dividend yield, the stock is cheap relative to its cash flow profile and differentiated specialty portfolio. This trade idea outlines a practical entr…
Nano Labs (NA) trades at a sub-$75M market cap after a strategic pivot into cryptocurrency reserves and a series of product and ecosystem moves. The combination of a very low price-to-book (0.66), a single-digit P/E (3.85), recent insider buying and technical signs of bullish momentum argue for a long trade with a 3x upside over the next 180 tradin…
Strattec (STRT) is executing an operational transformation that is translating into revenue growth, margin expansion and unusually high free cash flow. With a conservative balance sheet, attractive valuation and visible catalysts, the risk/reward favors a long position over the next 180 trading days. Entry $82.29, stop $72.00, target $105.00.
Centene (CNC) is trading at valuations that understate its cash-generation and exposure to Medicare rate upside. Recent CMS guidance and a beat on revenue give a path for margin betterment; pair that with a low EV/EBITDA and strong free cash flow and you have a high-conviction swing trade idea with defined risk.
<p>Perimeter Solutions (PRM) is a play on a stronger-than-normal wildfire season, improving underlying margins, and incremental upside from the recently closed MMT acquisition. The stock trades at $25.48 with positive technical momentum and a healthy free cash flow base; I’m initiating a long trade for the summer, looking for a re-rate toward a $33…
We like InfuSystem (INFU) as a long trade into 2026. The company pairs recurring rental and service revenue from infusion pumps and oncology support with improving profitability: free cash flow of $15.7M and an EPS base near $0.33 provide a credible path to revenue and margin expansion. At a market cap around $190M and an EV of $206M, the risk/rewa…
Doubleview Gold (DBLVF) is trading above its short- and medium-term moving averages with rising volume and compressed short interest. For traders willing to accept OTC-level risk and potential dilution, a disciplined long with a mid-term horizon captures a plausible M&A or news-driven re-rating.
Opera (OPRA) combines a high-single-digit revenue growth profile tied to advertising/search monetization with a 5.29% dividend yield and a cheap valuation (P/E ~12, PB ~1.3). Technicals show constructive momentum and short interest has been drifting lower. This is a pragmatic long trade for investors willing to hold through near-term volatility: en…
Sezzle appears to have completed a multi-month consolidation. With a cleaner operations narrative, improving merchant adoption and favorable seasonality ahead, the stock looks positioned for a re-rating. This is a mid-term swing trade with a defined entry at $1.20, a stop at $0.90 and a primary target at $2.40.
Eli Lilly's Foundayo approval is a structural positive for its obesity/weight-loss franchise, but near-term headline risk and pricing pressure in markets like India are already showing. I lay out a long trade that assumes disciplined launch execution and controlled margin impact, with a clear entry at $940.06, a stop at $880.00 and a target of $1,1…
